Ultragenyx shares crater after Angelman syndrome drug fails late-stage trial - Reuters
Ultragenyx shares crater after Angelman syndrome drug fails late-stage trial Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
All Coverage
<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxQRVVnMDdHSDRwc0ttZzdJZS1GcVhfS0MzcFUwRnRxQXFZZmV4TS1SNFU0Zk41N0FQb0M3VGNWOGpRMDFEclJlNWlJSEZYSUFUQzh2OEJ5M0VDZXEyZHFudnVINVE2TElIclRBSDRpc09ybE5uN0llcmFtVHFJXzRkU28xcWlkWmtoTmxlVDBLRlJ6Y2x0dHMzUjJMUmlzdzZMcXZCSDlac1FPNlZ4OTZMazB6YUYySjFfd3g5TlduaF9oMGsyTm1UcjI2TVIyYjNGRUkwQ3pybmxWcjkyd1FITXlR?oc=5" target="_blank">Ultragenyx shares crater after Angelman syndrome drug fails late-stage trial</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
Teva wins FDA approval for monthly schizophrenia injection Weltruza - Reuters
Teva wins FDA approval for monthly schizophrenia injection Weltruza Reuters
October 9, 2026 at 11:47 AMArgenx discontinues Vyvgart study in Sjögren's disease, shares tumble - Reuters
Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble Reuters
October 8, 2026 at 08:49 PMNvidia-backed Iambic Therapeutics launches IPO as biotechs buck market gloom - Reuters
Nvidia-backed Iambic Therapeutics launches IPO as biotechs buck market gloom Reuters
October 8, 2026 at 06:18 PMViatris bets on non-opioid pain drugs with $1.65 billion Pacira deal - Reuters
Viatris bets on non-opioid pain drugs with $1.65 billion Pacira deal Reuters
October 8, 2026 at 02:39 PMCSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis - Reuters
CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis Reuters
October 4, 2026 at 10:18 PMAbbVie joins US government pilot to test drug discount rebates - Reuters
AbbVie joins US government pilot to test drug discount rebates Reuters
October 2, 2026 at 08:53 PM